Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Pipeline Review, H1 2017

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0797TDB
  • |
  • Pages: 31
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Pipeline Review, H1 2017

Summary

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Kinase C Theta Type-Pipeline Review, H1 2017, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. The molecules developed by companies in Preclinical and Discovery stages are 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Infectious Disease, Oncology, Metabolic Disorders and Undisclosed which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflammation, Insulin Resistance, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Obesity, Prostate Cancer, Rheumatoid Arthritis, Type 2 Diabetes and Unspecified.

Furthermore, this report also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)

The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Overview

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Molecule Type

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Companies Involved in Therapeutics Development

AbbVie Inc

Astellas Pharma Inc

Celgene Corp

CompleGen Inc

Takeda Pharmaceutical Company Ltd

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Drug Profiles

AS-2521780-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-0739623-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-0471-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-1079-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

englerin A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PKC-Theta-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ewing Sarcoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Protein Kinase C Theta for Autoimmune Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Dormant Products

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)-Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by AbbVie Inc, H1 2017

Pipeline by Astellas Pharma Inc, H1 2017

Pipeline by Celgene Corp, H1 2017

Pipeline by CompleGen Inc, H1 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc, Astellas Pharma Inc, Celgene Corp, CompleGen Inc, Takeda Pharmaceutical Company Ltd

select a license

Single User License
USD 3500 INR 225960
Site License
USD 7000 INR 451920
Corporate User License
USD 10500 INR 677880

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com